Rovalpituzumab Tesirine (Rova-T) delivered disappointing preliminary results in the third-line setting for patients with relapsed/refractory small cell lung cancer with high DLL3 expression.
Original Article: Rova-T Underperforms in Phase II SCLC Trial
NEXT ARTICLE